Financials data is unavailable for this security.
View more
Year on year Abbott India Ltd grew revenues 9.35% from 53.49bn to 58.49bn while net income improved 26.52% from 9.49bn to 12.01bn.
| Gross margin | 45.28% |
|---|---|
| Net profit margin | 20.90% |
| Operating margin | 23.90% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Abbott India Ltd increased its cash reserves by 21.73%, or 520.70m. The company earned 12.13bn from its operations for a Cash Flow Margin of 20.74%. In addition the company used 4.16bn on investing activities and also paid 7.45bn in financing cash flows.
| Cash flow per share | 617.14 |
|---|---|
| Price/Cash flow per share | 45.02 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 127.78% and 26.52%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 0.93% |
|---|---|
| Div growth rate (5 year) | 52.32% |
| Payout ratio (TTM) | 70.32% |
| EPS growth(5 years) | 21.68 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 19.83 |
More ▼
